molnupiravir

Elana Gotkine THURSDAY, Dec. 29, 2022 (HealthDay News) -- For high-risk vaccinated adults, molnupiravir plus usual care does not reduce the frequency of COVID-19-associated hospitalizations or deaths,…

Elana Gotkine FRIDAY, Dec. 9, 2022 (HealthDay News) -- Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased…

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new study led by researchers in the Center…

FRIDAY, March 4, 2022 (HealthDay News) -- Molnupiravir is recommended for patients with nonsevere COVID-19…

The World Health Organisation (WHO) on Tuesday updated its therapeutic guidelines for Covid-19 to include the antiviral drug molnupiravir for patients with non-severe Covid-19 who are at highest risk of hospital admission.The drug is…

The study objective was to update the recently conducted review of Molnupiravir and to provide practical tips and guidelines for using the drug for COVID-19 patients by raising a few relevant, contemporary questions. A recent study…

TUCSON, Ariz., Jan. 17, 2022 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons (AAPS) condemns the continued hoarding by the federal government of hydroxychloroquine, which it has kept in a stockpile while expensive…

Tribune News Service Aditi TandonNew Delhi, January 12In its second warning against the use of Molnupiravir, the world’s first anti-Covid oral pill…

The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday. The ICMR’s National Task Force for COVID-19 has decided…

New Delhi, January 10 A majority of Covid patients during this Omicron-driven surge of infections have so far shown mild symptoms that can be managed at home with symptomatic treatment, an…